Vortioxetine’s Potential Against Glioblastoma. Could an Antidepressant Help Kill Brain Cancer?
Watch the Instagram video on the topic here!
By Dr. Nathan Goodyear
Glioblastoma, or GBM, is one of the most aggressive and deadly brain tumors, with standard treatments offering limited success. This has driven a need to explore new, more effective therapies. Interestingly, recent studies suggest that vortioxetine, a common antidepressant, could hold potential as part of this battle. So, could a medication initially designed for mood disorders offer hope against brain cancer? Let's dive in.
The Surprising Role of Drug Repurposing
Drug repurposing involves using approved medications for new therapeutic purposes, and it’s gaining popularity in cancer research. Vortioxetine, initially approved for treating depression, was recently identified as a potential anti-cancer agent. This discovery was made using high-throughput screening (HTS), a process that evaluates thousands of compounds quickly to find those with cancer-fighting properties.
Key Findings on Vortioxetine in GBM Research
1. Interfering with Cancer Pathways through Serotonin Modulation
Glioblastoma cells have serotonin receptors—yes, the same ones involved in mood regulation. Vortioxetine affects these receptors in a way that can disrupt the processes GBM cells need to grow and survive.
5-HT1A Receptor Modulation: This receptor, when influenced by vortioxetine, can interfere with pathways like MAPK, a pathway often dysregulated in cancer.
5-HT3 and 5-HT7 Receptor Blocking: By blocking these receptors, vortioxetine may reduce calcium influx in the cells and slow down GBM cell growth and survival.
2. Altering the Tumor Environment
Vortioxetine’s effects go beyond cancer cells themselves. The drug also influences BDNF (brain-derived neurotrophic factor), a key molecule in brain health. By regulating BDNF, vortioxetine could help make the brain environment less supportive of tumor growth, making it harder for GBM cells to thrive.
3. Inducing Cancer Cell Death (Apoptosis) and Halting Growth
Studies show that vortioxetine triggers GBM cells to undergo programmed cell death, known as apoptosis. It appears to do this by activating proteins that encourage cell death and suppressing those that prevent it. In GBM cells, vortioxetine:
Activates Caspase Pathways: These are pathways that lead to cell death.
Balances Pro- and Anti-apoptotic Proteins: It may increase levels of proteins that promote cell death (like Bax) and decrease those that prevent it (like Bcl-2).
Teaming Up with Standard Treatments
One of the most promising aspects of vortioxetine is its potential to work well with existing GBM treatments:
Enhancing Temozolomide (TMZ): Temozolomide is a standard chemotherapy for GBM, but some cells resist it. Vortioxetine may sensitize these cells to TMZ, helping it work more effectively.
Radiation Sensitization: The antidepressant could also make GBM cells more vulnerable to radiation, a common GBM treatment, by disrupting repair mechanisms that GBM cells use to survive after radiation.
Potential Mechanisms of Action: How Vortioxetine Fights Glioblastoma
Multi-targeted Approach: Vortioxetine works on several serotonin receptors that affect cell growth, survival, and death. This broad action is advantageous in targeting GBM from multiple angles.
Apoptosis and Cell Cycle Arrest: The drug promotes cancer cell death by influencing serotonin receptors and balancing proteins that regulate cell death.
Why Repurposing Vortioxetine Could Be a Game-Changer
Repurposing approved drugs like vortioxetine for GBM offers several advantages:
Quick Transition to Trials: Since vortioxetine is already FDA-approved, its safety profile is known, potentially speeding up its testing for GBM.
Adaptability for Different Patients: GBM is highly variable, so a drug that works in multiple ways could be more effective across various cases of this complex cancer.
However, challenges remain. While early lab studies show potential, additional animal and clinical studies are essential to understand how well vortioxetine can penetrate the brain and target GBM cells effectively.
Future Steps for Vortioxetine in GBM Therapy
Preclinical Studies: These animal studies are needed to ensure vortioxetine’s safety and effectiveness in live models.
Crossing the Blood-Brain Barrier (BBB): Understanding vortioxetine’s ability to reach the brain is crucial.
Clinical Trials: If the preclinical data supports its use, vortioxetine could move to human trials, where researchers would study its impact, dosing, and possible combinations with standard therapies.
Conclusion
Vortioxetine’s ability to target GBM cells through serotonin receptor modulation, influence brain health markers like BDNF, and work synergistically with existing treatments marks it as a promising candidate for glioblastoma treatment. While it may sound unusual to think of an antidepressant in the context of cancer, repurposing drugs is a powerful strategy in the search for more effective treatments. With further research, vortioxetine might prove to be an unexpected ally in the fight against GBM.
References
Lee, S., et al. (2024). High-throughput identification of repurposable neuroactive drugs with potent anti-glioblastoma activity. Nature Medicine. [DOI: 10.1038/s41591-024-03224-y]
